These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26536838)

  • 1. Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development.
    Vicini P; Fields O; Lai E; Litwack ED; Martin AM; Morgan TM; Pacanowski MA; Papaluca M; Perez OD; Ringel MS; Robson M; Sakul H; Vockley J; Zaks T; Dolsten M; Søgaard M
    Clin Pharmacol Ther; 2016 Feb; 99(2):198-207. PubMed ID: 26536838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How molecular medicine transforms policy (and everything else).
    Kean MA; Batchelder KF
    J Biolaw Bus; 2004; 7(3):16-9. PubMed ID: 15460603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice.
    LLerena A; Peñas-Lledó EM
    Drug Metab Pers Ther; 2015 Sep; 30(3):143-5. PubMed ID: 26353178
    [No Abstract]   [Full Text] [Related]  

  • 4. Variant discovery using next-generation sequencing and its future role in pharmacogenetics.
    Russell LE; Schwarz UI
    Pharmacogenomics; 2020 May; 21(7):471-486. PubMed ID: 32338137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways.
    Doherty M; Metcalfe T; Guardino E; Peters E; Ramage L
    Ann Oncol; 2016 Aug; 27(8):1644-6. PubMed ID: 27117532
    [No Abstract]   [Full Text] [Related]  

  • 6. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.
    Evans BJ
    Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crunch time for multiple-gene tests.
    Gewin V
    Nature; 2007 Jan; 445(7126):354-5. PubMed ID: 17251949
    [No Abstract]   [Full Text] [Related]  

  • 8. Current challenges in pediatric drug development.
    Adamson PC
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):883-4. PubMed ID: 19209138
    [No Abstract]   [Full Text] [Related]  

  • 9. Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward.
    Caudle KE; Keeling NJ; Klein TE; Whirl-Carrillo M; Pratt VM; Hoffman JM
    Pharmacogenomics; 2018 Jul; 19(10):847-860. PubMed ID: 29914287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA releases final guidance for pharmacogenomic data.
    Pharmacogenomics; 2005 Apr; 6(3):209. PubMed ID: 16013952
    [No Abstract]   [Full Text] [Related]  

  • 11. Label-free screening of single biomolecules through resistive pulse sensing technology for precision medicine applications.
    Harrer S; Kim SC; Schieber C; Kannam S; Gunn N; Moore S; Scott D; Bathgate R; Skafidas S; Wagner JM
    Nanotechnology; 2015 May; 26(18):182502. PubMed ID: 25875197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data in the molecular era-finding the reality in the real world.
    Dickson DJ; Pfeifer JD
    Clin Pharmacol Ther; 2016 Feb; 99(2):186-97. PubMed ID: 26565654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promise of personalized omics to precision medicine.
    Chen R; Snyder M
    Wiley Interdiscip Rev Syst Biol Med; 2013; 5(1):73-82. PubMed ID: 23184638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives.
    Prasad K; Breckenridge A
    Drug Discov Today; 2011 Oct; 16(19-20):867-72. PubMed ID: 21920454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Despite glacial progress, US government signals support for personalized medicine.
    Fox JL
    Nat Biotechnol; 2007 May; 25(5):489-90. PubMed ID: 17483821
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent updates and challenges on the regulation of precision medicine: The United States in perspective.
    Chang LC; Colonna TE
    Regul Toxicol Pharmacol; 2018 Jul; 96():41-47. PubMed ID: 29715491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: where we were and where we are.
    Challand R; Gorham H; Constant J
    J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
    Little S
    IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
    Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
    Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The increasing role of genetics and genomics in women's health.
    Klein EL
    Nurs Womens Health; 2014; 18(2):149-53. PubMed ID: 24750654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.